Abstract
Focus of brain tumour research is shifting towards tumour genesis and genetics, and possible development of individualized treatment plans. Genetic analysis shows recurrent mutation in isocitrate dehydrogenase (IDH1) gene in most Glioblastoma multiforme (GBM) cells. In this review we evaluated the prognostic significance of IDH 1 mutation on the basis of published evidence. Multiple retrospective clinical analyses correlate the presence of IDH1 mutation in GBM with good prognostic outcomes compared to wild-type IDH1. A systematic review reported similar results. Based on the review of current literature IDH1 mutation is an independent factor for longer overall survival (OS) and progression free survival (PFS) in GBM patients when compared to wild-type IDH1. The prognostic significance opens up new avenues for treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 816-817 |
| Number of pages | 2 |
| Journal | Journal of the Pakistan Medical Association |
| Volume | 67 |
| Issue number | 5 |
| Publication status | Published - May 2017 |
Keywords
- Glioblastoma multiforme
- IDH1 mutation
- Overall survival
- Progression free survival